Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

AimThe aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2.MethodsIn the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model.ResultsAmong 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0-1: 90.4% versus 79.7%; p=0.0002), more frequent GEJ localization (40.8% versus 27.6%; p=0.005), and lower platelet count (median: 298000 versus 335000/mm(3); p=0.02). In multivariate analyses, age<60years at diagnosis (HR 1.49, 95% CI 1.09-2.03, p=0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41-4.84, p=0.005) were the only significant poor prognostic factors for OS.ConclusionAge60years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS.